Upgrade

Finvezto Toolkit

Jubilant Pharmova Q2 FY27: revenue up 20.5% to ₹2,370 Cr, net profit down 74.1% to ₹31 Cr

Results · 16 Nov 2026 · Jubilant Pharmova (JUBLPHARMA)

Q2 FY27 results
Q2 FY27₹ CrYoY
Revenue2,370+20.5%
Operating profit241-29.6%
Net profit31-74.1%

In Q2 FY2027, revenue grew 21% year-on-year to Rs.2,370 Crores across all business segments, with EBITDA at Rs.255 Crores and profit after tax at Rs.31 Crores.

EBITDA margins declined year-on-year due to unavailability of high-margin SPECT radiopharma products, negligible third-party revenues, and remediation costs at the Montreal facility.

Management expects H2 revenue growth momentum to continue and margins to improve quarter-on-quarter to mid-teens on average as SPECT supplies from Montreal stabilize.

Company page · Results tracker

Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.